Adavanced Glycated Endproducts and Development of CAD

Study of Serum Level of Advanced Glycated Endproducts and Development of Coronary Atherosclerosis in Patients Undergoing Coronary Angiogram

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02089360

Acronym

AGENDA

Enrollment

10000

Registered

2014-03-17

Start date

2014-01-31

Completion date

Unknown

Last updated

2014-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Inflammation

Keywords

Advanced glycation end product, coronary, atherosclerosis, inflammation, outcome

Brief summary

Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.

Detailed description

Serum levels of HMGB1, HMGB2, ADAM10, etc. will be measured in lab and animal studies will be designed to intervene the adverse interaction between abnormal serum concentration of AGEs, etc. and worse clinical results.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention

Exclusion criteria

* patients underwent coronary angiogram for other reasons, including pre-surgery examination * patients with severe co-morbidity, and life expectancy less than one-year

Design outcomes

Primary

Measure	Time frame	Description
MACE	5-year	including death, occurrence of myocardial infarction, and coronary revascularization

Secondary

Measure	Time frame	Description
progression in coronary atherosclerosis	5-year	repeated coronary angiogram in patients with symptom aggravation or occurrence of myocardial infarction, to evaluate the progression of coronary lesions, comparing to the baseline results.

Other

Measure	Time frame	Description
Serum level of AGEs	baseline	serum levels of AGEs will be measured and the relationship between clinical outcomes will be analyzed.

Countries

China

Contacts

Primary ContactQi Zhang, PhD

rjheart@gmail.com86-21-64370045

Backup ContactWei Feng Shen, PhD

rjshenweifeng@gmail.com86-21-64370045

Outcome results